semaglutide cardiovascular outcomes news 2.4 mg delivered a statistically significant 20% risk reduction in major adverse events – REGENHEALTHSOLUTIONS (RHS) Oral Semaglutide and Cardiovascular Outcomes

These findings suggest that GLP-1 RAs may be more effective in reducing MI risk, primarily among patients with known ASCVD

This indicates an interesting GSH-dependent threshold regulation that is important for the subset-specific functions of B cells and a differential redox-dependent regulation of metabolic activities in these cells

Never take two doses in the same week to make up for a missed one, as this increases the risk of side effects

GLP-1 use is highest among people ages 50-64: 30% in this age group have ever taken them and 22% are currently using them

Peng D, Hu T, Soutto M, Belkhiri A, Zaika A, El-Rifai W

If the long-term cosmetic goals are concerned, consistent use is preferred